Blood pressure in heart failure management and prevention - Hypertension Research
Source : https://www.nature.com/articles/s41440-022-01158-x
Comparison between patients with and without heart failure regarding blood pressure The association between CV events and SBP is linear in patients without heart failure; however, it becomes J-shaped or...
Conclusions/Relevance: This review discusses the potential mechanisms by which hypertension leads to HFrEF or HFpEF, the impact of hypertension on incident heart failure, and the recommended approaches for blood pressure management in patients with heart failure.
Entrectinib-Induced Heart Failure in a Patient With Metastatic Lung Adenocarcinoma: A Case Report
Entrectinib is a recently approved multikinase inhibitor to treat advanced c-ros oncogene1 (ROS1) positive non-small cell lung cancer (NSCLC). Although molecular targeted therapy is generally well tolerated, cardiovascular adverse events...
Conclusions: We presented a case of symptomatic CTRCD after entrectinib treatment in a patient with ROS1-rearranged metastatic lung adenocarcinoma. Physicians should monitor cardiac function as patients may develop heart failure, especially in the early phase of entrectinib initiation. The number of cases where entrectinib is prescribed is...
Abnormal left ventricular subendocardial perfusion and diastolic function in women with obesity and heart failure and preserved ejection fraction - The International Journal of Cardiovascular Imaging
Source : https://link.springer.com/article/10.1007/s10554-022-02782-x
Purpose - Coronary microvascular dysfunction (CMD) is common in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Stress cardiovascular magnetic resonance (CMR) has been proposed as a...
Conclusion: Using a novel quantitative stress CMR myocardial perfusion mapping technique, women with obesity and HFpEF were found to have patterns of abnormal subendocardial perfusion which significantly correlated with measures of diastolic dysfunction.
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36565199/
Background Outcomes and treatment effects of therapy may vary according to the cause of heart failure (HF). Methods and Results In this post hoc analysis of the EMPEROR-Reduced (Empagliflozin Outcome...
Conclusions: Empagliflozin offers cardiovascular and renal benefits in patients with heart failure with reduced ejection fraction regardless of the cause of HF.
Constantly Bombarded with New Drugs: What's a Cardiologist to Do?
Source : https://journal.houstonmethodist.org/articles/10.14797/mdcvj.1179
Every physician encounters a barrage of direct-to-consumer and direct-to-physician advertising and is faced with the daunting task of deciding which drugs to add to their clinical armamentarium and how and...
Conclusions: This article focuses on a single drug, empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has been highly marketed in lay and medical media and hence has been incorporated into professional society treatment guidelines.
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36548322/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: While evidence of CV benefits grows, SGLT2 inhibitor prescribing has lagged, particularly among patients without diabetes. In the U.S., high cost and administrative hurdles may contribute to decreased patient and clinician uptake of this drug class. Future trial results and clinical experience with SGLT2 inhibitors may lead to...
Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial
Source : https://www.sciencedirect.com/science/article/abs/pii/S0002870322003258?via=ihub
Available online 8 December 2022 Author links open overlay panel Yu Horiuchi 1 2 # Yuya Matsue 2 Person # Envelope Show more The aim of the EMPA-AHF trial is...
Conclusion: The EMPA-AHF trial is the first to evaluate the efficacy and safety of early initiation of empagliflozin in patients with AHF considered to be at high risk under conventional treatment.
Adiposity and clinical outcomes in East Asian patients with heart failure and preserved ejection fraction
Source : https://www.sciencedirect.com/science/article/pii/S2352906722002111?via=ihub
Despite the obesity paradox, visceral adiposity is associated with poor clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). However, it remains unclear whether a relationship between...
Conclusions: In lean East Asian patients with HFpEF, a lower VAT volume was associated with poorer clinical outcomes. CT-based assessments of adiposity may provide incremental prognostic value over simple anthropometric indices in lean HFpEF patients.
The clinical relevance of quality of life in heart failure patients with preserved ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36510693/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: EQ-5D-5L is useful tool for risk stratification in patients with HFpEF.
Empagliflozin Proves Benefit in Pediatric Type 2 Diabetes in Phase 3 DINAMO Trial
New data suggests empagliflozin (Jardiance) use was associated with significant improvements in glycemic control among pediatric patients with type 2 diabetes. Announced in a December 7 statement from Eli Lilly...
New data suggests empagliflozin (Jardiance) use was associated with significant improvements in glycemic control among pediatric patients with type 2 diabetes. This study, “Diabetes study of Linagliptin and Empagliflozin in Children and Adolescents,” was presented at the International Diabetes Federation World Diabetes Congress 2022.
Therapeutic Efficacy of Shexiang Baoxin Pill Combined with Exercise in Patients with Heart Failure with Preserved Ejection Fraction: A Single-Center, Double-Blind, Randomized Controlled Trial - Chinese Journal of Integrative Medicine
Source : https://link.springer.com/article/10.1007/s11655-022-3627-3
Objective To evaluate the therapeutic efficacy of Shexiang Baoxin Pill combined with exercise in heart failure patients with preserved ejection fraction (HFpEF). Methods Sixty patients with HFpEF were randomly divided...
Conclusions: Exercise training improved exercise tolerance, sleep quality and quality of life (QoL) in patients with HFpEF. Notably, Shexiang Baoxin Pill played an active role in sleep quality and QoL of patients with HFpEF.
/>
Conclusion: In EMPEROR-Preserved, empagliflozin was effective and safe without SBP meaningfully moderating empagliflozin’s treatment effects. This analysis of EMPEROR-Preserved shows that empagliflozin can be used safely and effectively without blood pressure being a meaningful moderator of the drug benefit.
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis
Source : https://www.wjgnet.com/1949-8462/full/v14/i11/599.htm
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis Abdulbaril Olagunju, Naser Yamani, Dorothy Kenny, Martina Mookadam, Farouk Mookadam, Samuel Unzek Abdulbaril Olagunju,...
Conclusion: SGLT2-Is have a promising role in the management of MetS.
C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis - Current Heart Failure Reports
Source : https://link.springer.com/article/10.1007/s11897-022-00584-9
Purpose of Review The purpose of this review was to synthesize the evidence on non-traditional biomarkers from proteomic and metabolomic studies that may distinguish heart failure (HF) with preserved ejection...
Conclusions/Relevance: The results further suggest that HFpEF might be distinguishable from HFrEF based on higher levels of IL-6 and lower levels of SDC-1 and NO. These data may reflect pathophysiological differences between HFpEF and HFrEF.
Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of HFpEF - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35704032/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: These findings indicate that the GHRH receptor signalling pathway(s) represents a new molecular target to counteract dysfunctional cardiomyocyte relaxation by targeting myofilament phosphorylation and fibrosis. Accordingly, activation of GHRH receptors with potent, synthetic GHRH agonists may provide a novel therapeutic approach to...
Renin-angiotensin system inhibitor exerts prognostic effects in HFpEF patients with low baseline chloride level
Source : https://www.internationaljournalofcardiology.com/article/S0167-5273(22)01737-5/fulltext
Few interventions have shown improved prognosis in patients with heart failure and preserved ejection fraction (HFpEF). Serum chloride levels, which are affected by serum renin secretion, are associated with the...
Conclusion: RASi administration was associated with an improved prognosis only in HFpEF patients with a low baseline serum chloride level. Clinicians should consider RASi administration if patients' serum chloride levels are low, to improve the long-term prognosis of HFpEF patients.
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review - Cost Effectiveness and Resource Allocation
Source : https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-022-00396-7
Objectives This study was aimed to systematically review published economic studies to determine whether dapagliflozin, a sodium-glucose co-transporter inhibitor, plus standard care therapy (SCT) is cost-effective in heart failure with...
Conclusion: Results of cost-effectiveness analyses showed that adjunct dapagliflozin plus SCT is cost-effective compared to SCT alone despite the additional costs of the drug. Finally it can be concluded that dapagliflozin is a worldwide cost-effective as an adjunct medicine in HFrEF management.
-
Heart Failure Connect3yrKey Points • Source: Cost Effectiveness and Resource Allocation • Conclusion: “From the present systematic review results, it can be concluded that dapagliflozin, as a cardioprotective SGLT-2i, was cost-effective in most of the studied Show More
Conclusions: The authors conclude that the db/db aldosterone model may represent a distinct clinical subgroup of HFpEF that has marked hyperglycemia, obesity, and increased arrhythmia risk. This novel HFpEF model can be useful in future therapeutic testing and should provide unique opportunities to better understand disease pathobiology.
Right ventricular performance in patients with heart failure with mildly reduced ejection fraction: the forgotten ventricle - The International Journal of Cardiovascular Imaging
Source : https://link.springer.com/article/10.1007/s10554-022-02652-6
Right ventricular (RV) function is a major determinant of prognosis and adverse outcomes in patients with heart failure (HF). It is largely unknown if HF with mildly reduced ejection fraction...
Conclusions/Relevance: The present study shows a high prevalence of RV dysfunction in HFmrEF patients. Study findings provides some new insights on RV and LV systolic dysfunction coupling whereas RV diastolic dysfunction was not dependent on LV systolic dysfunction.
Longitudinal CMR assessment of cardiac global longitudinal strain and hemodynamic forces in a mouse model of heart failure - The International Journal of Cardiovascular Imaging
Source : https://link.springer.com/article/10.1007/s10554-022-02631-x
To longitudinally assess left ventricle (LV) global longitudinal strain (GLS) and hemodynamic forces during the early stages of cardiac dysfunction in a mouse model of heart failure with preserved ejection...
Conclusions/Relevance: Our results indicated that hemodynamic forces parameters were the only functional outcome measure that showed distinct temporal differences between groups. As such, changes in hemodynamic forces reflect early alterations in cardiac function which can be of added value in (pre)clinical research on HFpEF.